NORTHBROOK, Ill., March 4, 2010 (GLOBE NEWSWIRE) -- Nanosphere, Inc., (Nasdaq:NSPH), announced today it was selected one of the world's most innovative companies by Massachusetts Institute of Technology's Technology Review with its inclusion on the 2010 TR50 list.
The 2010 TR50 is Technology Review's first annual list identifying companies that demonstrate the most impressive and noteworthy innovations occurring in technology.
"In choosing the http://www.technologyreview.com/companywatch/tr50/">TR50, we picked companies with this year's most important inventions and breakthroughs. But we also selected companies that are successfully growing businesses and markets around innovative new products," said http://www.technologyreview.com/corp/leadership.aspx">Jason Pontin, editor in chief and publisher of http://www.technologyreview.com/">Technology Review. "The http://www.technologyreview.com/companywatch/tr50/">TR50 list is our selection of companies that show the most impressive innovation in commercializing new technologies."
"Nanosphere is a leader in commercializing microfluidic technology for use in clinical diagnostic tests, helping to pave the way for personalized medicine. The FDA's recent approval of its instrument for pharmacogenomic testing is a significant milestone," said David Rotman, editor, Technology Review.
Nanosphere joins such notable companies chosen by MIT's Technology Review as Amazon, GlaxoSmithKline, Google, Tesla Motors, and Twitter. It is one of six public bio-medical companies listed.
"To be recognized as an innovative global leader furthering healthcare and personalized medicine is gratifying," said William P. Moffitt, president and chief executive officer of Nanosphere, Inc. "Our focus on achieving excellence will continue to generate new solutions and breakthroughs that will improve diagnostic testing and ultimately the diagnosis and treatment of disease and the health of people worldwide."
The additional five selected public biomedical companies include Alnylam, AthenaHealth, GlaxoSmithKline, Illumina, and Medtronic. The list also acknowledged five private biomedicine companies including BIND Biosciences, Complete Genomics, Fate Therapeutics, Fluidigm, and Pacific Biosciences.
Nanosphere was also featured in the March/April edition of Technology Review, with a focus on the company's Verigene® System, troponin testing and overall approach to personalized medicine. The link to the online version is: http://www.technologyreview.com/biomedicine/24581/
About 2010 TR50
The first annual list compiled by MIT's Technology Review, Inc. recognizes companies of all sizes, both public and private, within the energy, computing, web, biomedicine, and materials sectors that have demonstrated the most promising technologies and remarkable potential to transform the world. Companies were evaluated on their business model, strategies for deploying and scaling up their technologies, and the likelihood of success. For more information and full access to the list, please visit: http://www.technologyreview.com/companywatch/tr50/
About Technology Review, Inc.
Technology Review, Inc., an independent media company owned by MIT, is the authority on the future of technology, identifying emerging technologies and analyzing their impact for leaders. Technology Review's media properties include Technology Review magazine, the oldest technology magazine in the world (founded in 1899); the daily news website TechnologyReview.com; and events such as the annual EmTech@MIT Conference.
About Nanosphere, Inc.
Nanosphere develops, manufactures, and markets an advanced molecular diagnostics platform, the Verigene® System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
The Nanosphere, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4344